CVS
A better-than-expected quarter
CVS Health came out swinging with first-quarter adjusted EPS of $2.57, easily clearing the Street’s $2.20 estimate. Revenue hit $100.43 billion, up 6.2% year over year, so this wasn’t one of those “we beat on earnings by cutting the lights off” situations. The company also said it now expects 2026 adjusted EPS of $7.30 to $7.50, up from its prior $7.00 to $7.20 range.
The part investors actually care about
That higher guide is the real sauce here. CVS is telling the market that its business is running a little hotter than expected, and that matters because health care conglomerates live and die by confidence. If management can keep the execution train on the tracks, the market tends to reward the boring-but-profitable stuff.
Wall Street noticed, naturally
Analysts didn’t exactly sit on their hands after the report:
- Evercore ISI kept an Outperform rating and bumped its target to $105 from $100
- Truist kept Buy and raised its target to $102 from $98
- Barclays stayed Overweight and lifted its target to $101 from $93
- RBC kept Outperform and raised its target to $107 from $93
That’s a pretty clear “we like what we’re seeing” chorus. CVS shares were down just 0.1% to $86.74 on Thursday, which suggests the market is still in wait-and-see mode rather than throwing a parade.
Big picture
CVS is trying to prove that its sprawling health care machine can still deliver clean execution and better profits, even in a sector that loves to make simple things complicated. If the upgraded guidance sticks, this could be another step toward convincing investors the turnaround is more than just corporate pep talk.